Previous close | 134.00 |
Open | 132.79 |
Bid | 137.80 x 500 |
Ask | 137.95 x 500 |
Day's range | 132.48 - 138.50 |
52-week range | 74.75 - 142.00 |
Volume | |
Avg. volume | 3,081,608 |
Market cap | 54.6B |
Beta (5Y monthly) | 1.21 |
PE ratio (TTM) | 106.05 |
EPS (TTM) | 1.30 |
Earnings date | 25 Apr 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 151.32 |
Based on the average brokerage recommendation (ABR), DexCom (DXCM) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
DexCom's (DXCM) first-quarter 2024 results are likely to reflect rising volumes across all channels.
Beyond analysts' top -and-bottom-line estimates for DexCom (DXCM), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.